Trial Profile
The comparison of azilsartan and amlodipine for treatment of VEGF receptor-tyrosine kinase inhibitor-induced hypertension in advanced kidney cancer patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Jun 2018
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Azilsartan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- 18 May 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Jun 2013 New trial record